Market Research Logo

Global Schizophrenia Therapeutics Market 2017-2021

Global Schizophrenia Therapeutics Market 2017-2021

About Schizophrenia Therapeutics

Schizophrenia is a chronic mental disorder that alters the perception, thinking, and social behavior of an individual. Individuals suffering from this disease face difficulty in distinguishing between imaginary things and reality. Although schizophrenia is not as prevalent as other mental disorders, it affects 7 or 8 individuals out of 1,000 people. Globally, the disease affects 1% of the total population. Schizophrenic patients are usually diagnosed with low levels of dopamine and serotonin. These are major neurotransmitters in the brain and are responsible for transmitting nerve signals from one neuron to another neuron. Deficiency of these neurons in the brain leads to impairment of thinking, perception, and the activity of an individual. At present, the treatment regimen for this disease focuses on relieving symptoms. Thus, antipsychotic drugs are used as a standard treatment regimen for schizophrenia. It helps in reversing the low levels of dopamine and serotonin, thereby improving the patient's condition. Technavio’s analysts forecast the global schizophrenia therapeutics market to grow at a CAGR of 1.84% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global schizophrenia therapeutics market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Schizophrenia Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AstraZeneca
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson
Other prominent vendors
  • Alkermes
  • Bristol-Myers Squibb
Market driver
  • Increasing expenditure on prescription drugs
  • For a full, detailed list, view our report
Market challenge
  • Technological advances in non-invasive neuromodulation devices
  • For a full, detailed list, view our report
Market trend
  • Increase in use of LAI antipsychotic drugs
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Releases

Technavio Announces the Publication of its Research Report – Global Schizophrenia Therapeutics Market 2017-2021

Technavio recognizes the following companies as the key players in the global schizophrenia therapeutics market: AstraZeneca, Eli Lilly, GlaxoSmithKline, and Johnson & Johnson.

Other Prominent Vendors in the market are: Alkermes and Bristol-Myers Squibb.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is Increase in use of LAI antipsychotic drugs. The global schizophrenia therapeutics market is witnessing an increase in the popularity of LAI antipsychotics, as they can attain higher efficacy in negative and cognitive predominant patients. LAI antipsychotics are administered once every two or four weeks (depending on the specific drug). They improve patient compliance, which is important for long-term maintenance of therapeutic drugs, and are associated with both reduced hospitalization rates and reduced care costs.”

According to the report, one of the major drivers for this market is Increasing expenditure on prescription drugs. The global schizophrenia therapeutics market witnessed a large shift in the clinical and economic role of prescription drugs because of the policy changes in the healthcare sector, availability of insurance coverage, introduction of behavioral healthcare techniques, and marketing strategies adopted by pharmaceutical companies to promote their products. All these efforts have positively influenced the prescription value of antipsychotic drugs.

Further, the report states that one of the major factors hindering the growth of this market is Technological advances in non-invasive neuromodulation devices. The majority of schizophrenic population treated with antipsychotic drugs continue to suffer from their side effects such as weight gain, muscle spasm, blurred vision, dry mouth, and drowsiness. Hence, alternative methods were being investigated, and devices were developed for the individuals who do not respond to medications.

Companies Mentioned

AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Alkermes and Bristol-Myers Squibb.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Market outline
      • Table Parts of brain affected by schizophrenia
      • Table Prevalence rate of disease
      • Table Reduction in prescription revenue over the years for antipsychotic drugs due to entry of generics
  • Schizophrenia: Disease overview
    • Schizophrenia
    • Medical intervention for treating schizophrenia
      • Table Types of antipsychotic drugs
      • Table Use of antipsychotic in schizophrenia
      • Table Symptoms of disease
    • Non-medical interventions for treating schizophrenia
      • Table Non-medical treatment interventions
  • Key clinical trials
    • Table Pipeline landscape based on number of molecules
    • Table Key clinical trials in global schizophrenia therapeutics market 2016
    • Table Snapshot of pipeline trends in global schizophrenia therapeutics market
  • Market landscape
    • Market overview
      • Table Global schizophrenia therapeutics market snapshot
    • Market size and forecast
      • Table Global schizophrenia therapeutics market 2016-2021 ($ millions)
      • Table Global schizophrenia therapeutics market: Opportunity analysis
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation based on drugclass
    • Table Market segmentation of global schizophrenia therapeutics market by drug-class
    • Table Global schizophrenia therapeutics market segmentation by drug-class
    • Table Global schizophrenia market revenue by drug-class, 2016-2021 (in $ millions)
    • First-generation antipsychotic drugs
      • Table Global schizophrenia first-generation antipsychotic drugs market 2016-2021 ($ millions)
    • Second-generation antipsychotic drugs
      • Table Global schizophrenia second-generation antipsychotic drugs market 2016-2021 ($ millions)
    • Third generation antipsychotic drugs
      • Table Global schizophrenia third-generation antipsychotic drugs market revenue 2016-2021 ($ millions)
  • Geographical segmentation
    • Market overview based on geography
      • Table Global schizophrenia therapeutics market share by geography, 2016 and 2021
      • Table Global schizophrenia therapeutics market revenue by geography, 2016-2021 ($ millions)
      • Table Global schizophrenia therapeutics market share by geography, 2016-2021
    • Schizophrenia therapeutics market in Americas
      • Table Market scenario in Americas
      • Table Schizophrenia therapeutics market in Americas 2016-2021 ($ millions)
    • Schizophrenia therapeutics market in EMEA
      • Table Market scenario in EMEA
      • Table Schizophrenia therapeutics market in EMEA 2016-2021 ($ millions)
    • Schizophrenia therapeutics market in APAC
      • Table Market scenario in APAC
      • Table Schizophrenia therapeutics market in APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
    • Market challenges
      • Table Psychotic symptoms
  • Market trends
    • Rising public interest toward mental health
    • Increase in use of LAI antipsychotic drugs
    • Availability of drugs with novel mechanism of action (MoA)
  • Vendor landscape
    • Competitive landscape
      • Table Competitive structure analysis of global schizophrenia drugs market 2016
  • Key vendor analysis
    • AstraZeneca
      • Table AstraZeneca: Strength assessment
      • Table AstraZeneca: Strategy assessment
      • Table AstraZeneca: Opportunity assessment
      • Table AstraZeneca: Revenue garnered by SEROQUEL XR and SEROQUEL IR 2014-2015 ($ millions)
    • Eli Lilly
      • Table Eli Lilly: Key highlights
      • Table Eli Lilly: Strength assessment
      • Table Eli Lilly: Strategy assessment
      • Table Eli Lilly: Opportunity assessment
    • GlaxoSmithKline
      • Table GlaxoSmithKline: Key highlights
      • Table GlaxoSmithKline: Strength assessment
      • Table GlaxoSmithKline: Strategy assessment
      • Table GlaxoSmithKline: Opportunity assessment
    • Johnson & Johnson
      • Table Johnson & Johnson: Key highlights
      • Table Johnson & Johnson: Strength assessment
      • Table Johnson & Johnson: Strategy assessment
      • Table Johnson & Johnson: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report